Every effort will be made to i nclude patients of racial and ethnic minorities who fulfill the eligibility criteria. 4.5 Randomization Patients will be randomized in a 1:1 ratio to one of 2 treatmen t arms (see Study Schema ). Because our data showed that T cell function is associated with the tumor g rade, the randomization will be   ǣζ͹ͺ -10. Treatment allocation will be determined by a computer- generated permuted-block randomization scheme developed and mai ntained by the Department of Oncology Biostatistics at Johns Hopkins. Randomization will be performed by the study statistician, Marianna Zahurak, MS. This pre-generated randomization scheme h as been approved by the Johns Hopkins Research Pharmacy, who will also maintain a copy of the scheme. 5. STUDY PLAN 5.1 Overview and Schema This is a single-center, randomized, 2-arm, open-label, prospec tive clinical trial evaluating the immunogenicity and safety of a single administration of LHRH an tagonist (degarelix) used alone, or degarelix administered in sequence with low-dose cyclophosphami de and GVAX, given 3 weeks prior to radical prostatectomy in men with localized prostate c ancer. Patients will be recruited from the outpatient Urology clinic. Eligible patients will be randomized in ͳǣͳȋ  ǣζ͹ͺ -10) to receive one of two treatment regimens ( see Schema below ), each beginning 28 (±3) days prior to radical prostatectomy. In Arm B, Cyclophosphamide will be given at a dose of 200 mg/m2 as a single intravenous infusion. 1 day later, prostate GVAX will be administered as five 0.8-mL intrad ermal injections of PC3 (2.5 × 108 cells) and five 0.5-mL intradermal injections of LNCaP (1.6 × 1 08 cells), for a total dose of 4.1 × 108 cells. On day 14, Degarelix acetate will be administered as th ree 80 mg subcutaneous injections, for a total dose of 240 mg. Prostate glands will be harvested 14 ( ±3) days later, at the time of radical prostatectomy, and prostate tissue will be examined for the pri mary endpoint. In Arm A, an identical dose of degarelix acetate will be administered 14 (±3 ) days prior to surgery. A telephone follow-up interview (or an in-person clinic visit) to evaluate for adverse events will occur 28 (±21) days after prostatectomy. Patients will then be followed by the ir urologists according to standard institutional practices, but will require PSA evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-3. Treatment Schema: . Androgen suppression with prostate GVAX and cyclophosphamide J1265 Johns Hopkins University 24 of 68 J1265 PROT (Vers) 1.4 113012 Table 1 A STUDY CALENDAR for ARM A (Androgen-Ablation Alone) Every effort should be made to keep visits, tests, and procedures on schedule. Acceptable deviations are listed below . ARM A Screening Evaluation a Day 14 Radical Prostatectomy, Day 28 (±3) Follow -up, 28 Days (±21 ) Post -op l m Informed consent X Medical history X X Review of medications X X Physical examination X X Vital signs X X Height and weight X Performance status X X X CT and bone scan b (X) Hematology labs c X X X Chemistry labs d X X X Serum PSA e X X HLA t yping f X Sera for immunoassays g X X X Blood ( 200 mL) for PBLs h X X Degarelix acetate dose i X Toxicity assessment X----------- ------------------------------------------------------- X Vaccine site assessment X------------------------------------------------------------------ X Surgical specimen j X Pathologic review k X X a: The screening (pre -treatment) evaluation should be conducted within 3 weeks (±4 days) of starting protocol therapy. b: Staging CT (i f allergic to CT scan contrast, obtain MRI with contrast) and bone scans should only be performed if clinically indicated, and are not mandatory.